CHU Dijon Bourgogne ( Site 0320)
Dijon, Cote-d Or 21000
0 studies enrolling now · 1 studies all time
What they study most
Melanoma
Studies at this site
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
— Running, not enrolling